(Q37053313)

17 August 2017

1 reference

title

Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches (English)

1 reference

17 August 2017

1 reference

Hao Lin

1

1 reference

17 August 2017

Chan-Chao Changchien

series ordinal

2

1 reference

17 August 2017

publication date

1 December 2007

1 reference

Taiwanese Journal of Obstetrics & Gynecology

17 August 2017

published in

1 reference

17 August 2017

volume

46

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

379-388

1 reference

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Oral etoposide is active against platinum-resistant epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Cellular response to a glutathione S-transferase P1-1 activated prodrug.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Advanced epithelial ovarian cancer: 1998 consensus statements

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960007-8

7 January 2021

10.1016/S1028-4559(08)60007-8

Identifiers

DOI

1 reference

17 August 2017

1 reference